Mihai Miron, owner of Ropharma Bra[ov (RPH) pharmaceuticalcompany, transferred yesterday to the first tier of the BSE,believes Romania's pharmaceutical market is currently the mostdynamic in the region, and is likely to reach a level of around10bn euros in the next seven years should state authorities keeptheir pledges about the healthcare sector.
"In Romania, unfortunately, the average expenses per capita fordrugs stand at 100 euros, while the European average goes beyond500 euros. We have a lot of catching up to do, and under thecircumstances, my projections show the market could go as high as10bn euros in the next seven years," Miron stated.
At present, the pharmaceutical product market revolves around 2bneuros and in terms of value it is still on the rise despite thecrisis.
Miron explained the level of the state's healthcare expenditureswas set to rise considering the Government has pledged to raise theminimum salary in the following years, with employees' andemployers' contributions for healthcare poised to go upimplicitly.
As far as his business is concerned, the Ropharma Bra[ov majorityshareholder says the arrearage in the healthcare system has notaffected it that much as he has financing available "under verygood terms for this market." Miron says he has a line of creditwith an interest rate of 2.5% above EURIBOR (that is 3.5% a year),considering some local banks are paying 4% for euro deposits.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
